Results 11 to 20 of about 12,742 (223)

Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults [PDF]

Drug Design, Development and Therapy, 2013
Marco MulaDivision of Neurology, Trinity Hospital, Borgomanero, ItalyAbstract: Epilepsy is one of the most common neurologic disorders, affecting about 50 million people around the world.
Mula M
doaj   +4 more sources

Zonisamide [PDF]

Epilepsia, 1999
Summary:Zonisamide (ZNS) is a broad‐spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. It is effective for both localization‐related and generalized epilepsies and appears to be particularly potent in progressive myoclonic epilepsy syndromes.
openaire   +2 more sources

Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. [PDF]

, 2016
BACKGROUND: Prior studies have shown that switching patients from inducing antiepileptic drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum lipids and C-reactive protein (CRP). These studies were all of short duration, and some drugs,
Chervoneva, Inna, Miller, Rachael, Mintzer, Scott, Nei, Maromi, Shah, Krunal, Skidmore, Christopher T., Sperling, Michael R.   +6 more
core   +2 more sources

The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs [PDF]

, 2019
Up to date, preclinical screening for new antiepileptic substances is performed by a combination of different in vivo models of acute seizures, for which large numbers of animals are necessary.
Dag, Ramazan, Fidzinski, Pawel, Heuzeroth, Hanno, Holtkamp, Martin, Wawra, Matthias   +4 more
core   +1 more source

Zonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease (ZEAL Study): A Protocol for Randomized Controlled Trials

Frontiers in Neurology, 2021
Background: Sleep disorders are one of the most frequent non-motor symptoms of Parkinson's disease (PD), and the efficacy of dopaminergic agents remains controversial.
Hiroshi Kataoka, Masahiro Isogawa, Takashi Inoue, Miyoko Hasebe, Ryuzo Takashima, Shu Kasama, Hitoki Nanaura, Takao Kiriyama, Masato Kasahara, Kazuma Sugie   +9 more
doaj   +1 more source

2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs [PDF]

, 2016
This report represents a scientific and working clinical consensus statement on seizure management in dogs based on current literature and clinical expertise.
Bunch SE, Bunch SE, Cheuk DK, Cunningham JG, Dayrell‐Hart B, Durkes TE, Dyer KR, E.E. Patterson, Farnbach GC, Farnbach GC, Forrester SD, Frey HH, Gaskill CL, Gaskill CL, H.A. Volk, Jacobs G, Jennings PB, K. Muñana, Kantrowitz LB, M. Berendt, M. Podell, March PA, Masuda Y, Nichols ES, Patterson E, Pearce L, Pedersoli WM, Perrucca E, Poffenbarger EM, Ravis WR, S.R. Platt, Schwartz‐Porsche D, Schwartz‐Porsche D, Steinberg M, Thurman GD, Trepanier LA, Trepanier LA, W. Löscher   +37 more
core   +2 more sources

Effects of Chronic Administration of Zonisamide, an Antiepileptic Drug, on Bone Mineral Density and Their Prevention With Alfacalcidol in Growing Rats

Journal of Pharmacological Sciences, 2003
We investigated the effects of chronic administration of zonisamide, an antiepileptic agent, on bone metabolism in growing rats. Administration of zonisamide at a dose of 80 mg/kg per day, s.c.
Atsushi Takahashi, Kenji Onodera, Junzo Kamei, Shinobu Sakurada, Hisashi Shinoda, Shuichi Miyazaki, Takashi Saito, Hideaki Mayanagi   +7 more
doaj   +1 more source

Moderate toxic effects following acute zonisamide overdose [PDF]

, 2011
Zonisamide is an antiepileptic drug that acts on voltage-sensitive sodium and calcium channels, with a modulatory effect on GABA-mediated neuronal inhibition and an inhibitory effect on carbonic anhydrase.
Ceschi, A, Hofer, K E, Kullak-Ublick, G A, Kupferschmidt, H, Rauber-Lüthy, C, Trachsel, C   +5 more
core   +1 more source

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease

Parkinson's Disease, 2018
Zonisamide is a relatively recent drug for Parkinson’s disease. Multiple hypotheses have been proposed to explain the antiparkinsonian effects of zonisamide.
Haruo Nishijima, Yasuo Miki, Shinya Ueno, Masahiko Tomiyama   +3 more
doaj   +1 more source

Efficacy of zonisamide: our experience [PDF]

, 2003
The current overview of zonisamide use and effectiveness is based on both a long-term prospective postmarketing survey and current zonisamide use at the Saitama Medical College, Department of Neuropsychiatry.
Yamauchi, Toshio, Aikawa, Hiroshi
core   +1 more source